Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M790Revenue (TTM) $M69.4Net Margin (%)15.6Altman Z-Score2.9
Enterprise Value $M701EPS (TTM) $0.2Operating Margin %18.9Piotroski F-Score6
P/E(ttm)75.1Beneish M-Score1.6Pre-tax Margin (%)18.1Higher ROA y-yY
Price/Book7.510-y EBITDA Growth Rate %--Quick Ratio9.1Cash flow > EarningsY
Price/Sales11.45-y EBITDA Growth Rate %--Current Ratio9.1Lower Leverage y-yN
Price/Free Cash Flow53.4y-y EBITDA Growth Rate %--ROA % (ttm)7.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)11.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M70.2ROIC % (ttm)81.6Gross Margin Increase y-yN

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PGNX is held by these investors:



PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Broadfin Healthcare Master Fun10% Owner 2017-02-15Sell602,600$9.6616.56view
Broadfin Healthcare Master Fun10% Owner 2017-02-09Sell351,300$9.7115.96view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.8364.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$760.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.8364.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.4973.5view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.0659.49view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.0759.26view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$760.86view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.8364.86view

Press Releases about PGNX :

Quarterly/Annual Reports about PGNX:

News about PGNX:

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
8:31 am Progenics Pharm announces the publication of previously-reported results from the Phase 2... Mar 24 2017
Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of... Mar 24 2017
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17,... Mar 17 2017
PROGENICS PHARMACEUTICALS INC Financials Mar 15 2017
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 09 2017
Progenics reports 4Q loss Mar 09 2017
Progenics reports 4Q loss Mar 09 2017
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business... Mar 09 2017
Progenics Pharmaceuticals (PGNX) in Focus: Stock Gains 8.3% Feb 28 2017
Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9 Feb 23 2017
Biotech Premarket Movers: Progenics, Alexion, BioCryst Feb 16 2017
Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600 Feb 15 2017
Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted... Feb 14 2017
Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences Feb 08 2017
Progenics Pharm upgraded by Needham Feb 06 2017
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : January 30, 2017 Jan 30 2017
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Jan 30 2017
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US :... Jan 27 2017
ETFs with exposure to Progenics Pharmaceuticals, Inc. : January 20, 2017 Jan 20 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)